NBIX
More runway for Crenessity
Neurocrine Biosciences is back with another dose of good news for CRENESSITY (crinecerfont), this time from the Phase 3 CAHtalyst Pediatric study. The company says two-year data showed durable control of the hormone chaos tied to classic congenital adrenal hyperplasia, while also allowing patients to stay on lower, more physiologic glucocorticoid doses.
That matters because CAH is one of those diseases where the treatment tradeoff can feel annoyingly unfair: manage the underlying problem, but then pile on steroid exposure that can create a whole new set of issues. Neurocrine is trying to show Crenessity can help patients thread that needle better.
What stood out
Among the headline numbers:
- 60% of patients who were overweight or obese at baseline saw clinically meaningful improvements in BMI
- 61% of patients with insulin resistance at baseline were no longer insulin resistant
- Improvements were also seen in acne and the androstenedione-to-testosterone ratio
- ACTH and 17-OHP stayed suppressed, which is the kind of boring-but-important biology investors like to see when a drug is trying to become a real standard of care
Why investors should care
This isn’t just a “nice data update” cameo. Neurocrine is building a case that Crenessity can deliver both biochemical control and a quality-of-life benefit over time, which is exactly the combo that can support uptake, physician confidence, and pricing power.
If the drug keeps stacking up longer-term data like this, the market may start thinking less about a launch and more about a franchise. Big difference.
Big picture: two-year durability is where hopeful biotech stories either level up or quietly fade away. Neurocrine just gave bulls a little more ammo.